

A Habenula Neural Biomarker Simultaneously Tracks Weekly and Daily Symptom Variations during Deep Brain Stimulation Therapy for Depression

Shi Liu^{1,2,3,9}, Yu Qi^{1,3}, Shaohua Hu⁴, Ning Wei⁴, Jianmin Zhang⁵, Junming Zhu⁵, Hemmings Wu⁵, Hailan Hu⁶, Yuxiao Yang^{1,2,3,5,7*} and Yueming Wang^{1,3,8*}

¹ MOE Frontier Science Center for Brain Science and Brain-machine Integration, Nanhu Brain-computer Interface Institute, Hangzhou, 310058, China.

² State Key Laboratory of Brain-machine Intelligence, Hangzhou, 311100, China.

³ College of Computer Science and Technology, Zhejiang University, Hangzhou, 310058, China.

⁴ Department of Psychiatry, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.

⁵ Department of Neurosurgery, The Second Affiliated Hospital of Zhejiang University, Hangzhou, 310058, China.

⁶ School of Brain Science and Brain Medicine, Zhejiang University, Hangzhou, 310058, China.

⁷ NHC and CAMS Key Laboratory of Medical Neurobiology, Zhejiang University, Hangzhou, 310058, China.

⁸ Qiushi Academy for Advanced Studies, Zhejiang University, Hangzhou, 310058, China.

⁹ Lingang Laboratory, Shanghai, 200031, China.

* Corresponding author(s). E-mail(s): yuxiao.yang@zju.edu.cn; yumingwang@zju.edu.cn

Running title: A Habenula Biomarker for Depression DBS Therapy

Keywords: deep brain stimulation; treatment-resistant depression; habenula; local field potential; neural biomarker; machine learning

Abstract

31
32 Deep brain stimulation (DBS) targeting the lateral habenula (LHb) is a promising
33 therapy for treatment-resistant depression (TRD) but its clinical effect has been
34 variable, which can be improved by adaptive DBS (aDBS) guided by a neural
35 biomarker of depression symptoms. A clinically-viable neural biomarker is desired to
36 classify depression symptom states, track both slow and fast symptom variations
37 during the treatment, and respond to DBS parameter alterations, which is currently
38 lacking. Here, we conducted a study on one TRD patient who achieved remission
39 following a 41-week LHb DBS treatment, during which we assessed slow symptom
40 variations using weekly clinical ratings and fast variations using daily self-reports.
41 We recorded daily LHb local field potentials (LFP) concurrently with the reports
42 during the entire treatment process. We then used machine learning methods to
43 identify a personalized depression neural biomarker from spectral and temporal LFP
44 features. The identified neural biomarker classified high and low depression symptom
45 severity states with a cross-validated accuracy of 0.97. It further simultaneously
46 tracked both weekly (slow) and daily (fast) depression symptom variation dynamics,
47 achieving test data explained variance of 0.74 and 0.63, respectively. It finally
48 responded to DBS frequency alterations. Our results hold promise to identify
49 clinically-viable neural biomarkers to facilitate future aDBS for treating TRD.

50 51 **1. Introduction**

52 Major depressive disorder (MDD) is one of the most common neuropsychiatric
53 disorders, affecting over 300 million individuals worldwide [1] . Approximately 30%

54 of MDD patients are treatment-resistant, meaning they do not respond adequately to
55 at least two antidepressant trials [2]. Deep brain stimulation (DBS) is a neurosurgical
56 procedure that allows targeted circuit-based neuromodulation [3]. It has emerged as a
57 promising treatment option for patients with treatment-resistant depression (TRD) [4–
58 6], as shown by open-label studies targeting various brain structures involved in the
59 brain’s “reward” system that mediates positive motivations. Such targets include the
60 subcallosal cingulate cortex (SCC) [7], the ventral capsule/ventral striatum (VC/VS)
61 [8], the medial forebrain bundle (MFB) [9], and the bed nucleus of the stria terminalis
62 (BNST) [10]. However, several recent double-blinded clinical trials have shown that
63 the effects of DBS targeting these brain structures are inconsistent across patients
64 [11–15]. As a potential improvement over DBS, adaptive DBS (aDBS) optimizes
65 DBS parameters in real-time by using neural signals as feedback for enhancing
66 clinical efficacy [16]. A recent study implements aDBS targeting VC/VS in a TRD
67 patient by triggering stimulation only when the local field potential (LFP) signal
68 pattern indicates worsening of depression symptoms, achieving rapid alleviation of
69 depression symptoms [17].

70 The lateral habenula (LHb) is a hub structure that plays a central role in the brain’s
71 “anti-reward” system that mediates negative motivations [18–20]. Animal studies
72 have systematically shown that the local bursting firing patterns in LHb are closely
73 related to depression-like behaviors and that neuromodulation of LHb has significant
74 antidepressant effects [21,22]. Several clinical studies have reported single-patient
75 depression symptom alleviation following LHb DBS since 2010 [23–26]. On the
76 other hand, two recent clinical studies on seven or six patients has shown more
77 variable effects of LHb DBS across patients [27,28] Similar to other DBS targets,

78 aDBS for LHb also provides a promising path towards improved and more consistent
79 treatment effects across TRD patients.

80 A critical and fundamental requirement for developing LHb aDBS is the
81 identification of an LHb neural biomarker of depression symptoms during the DBS
82 treatment to provide the necessary feedback signal [29,30]. A population-level SCC
83 LFP spectral power biomarker has been identified for tracking depression symptom
84 recovery with SCC DBS in five TRD patients [31]. Personalized amygdala and BNST
85 LFP gamma power biomarkers have been identified for optimizing VC/VS DBS [32].
86 For LHb DBS, LFP signals have been recorded before the DBS treatment starts but
87 not during the multi-month-long treatment process [27,28,33] and several studies
88 have found statistical correlations between pre-treatment LHb LFP spectral features
89 and after-treatment depression symptom ratings [27,28,33]. However, it is unknown
90 whether the identified LFP features can classify depression symptom severity states
91 or track the temporal dynamics of depression symptom variations during the DBS
92 treatment process. Therefore, a useful neural biomarker for realizing LHb aDBS is
93 still lacking.

94 A clinically-viable neural biomarker is desired to be able to track both the slow
95 and fast temporal dynamics of depression symptom variations during DBS. This is
96 because both natural and DBS-induced depression symptom changes can vary at
97 different time scales, with both slow-changing dynamics over months or weeks [34–
98 38] and fast-changing dynamics over hours or days [9,39–42]. Existing neural
99 biomarker studies have focused on tracking the temporal dynamics of either slow or
100 fast symptom variations. The aforementioned SCC neural biomarker for SCC DBS
101 tracks the temporal dynamics of the weekly symptom variations over 24 weeks [31].

102 The aforementioned amygdala and BNST neural biomarkers for VC/VS DBS track
103 the faster temporal dynamics of symptom variations within several days [17,32].
104 Several other studies have also identified resting-state (without DBS) neural
105 biomarkers of relatively fast depression symptom variations within several days using
106 multisite intracranial electroencephalography (iEEG) [43–45]. However, to date,
107 identifying a neural biomarker that can simultaneously track the temporal dynamics
108 of both slow and fast depression symptom variations, in particular during LHb DBS
109 treatment, remains elusive.

110 Moreover, the neural biomarker needs to reflect the dose effect of different DBS
111 parameters for optimizing stimulation parameters in aDBS. Since the DBS
112 mechanism for treating TRD is largely unknown [46], only few studies have
113 experimentally explored the dose effect of different DBS amplitudes on human neural
114 signals [17,31,32]. On the other hand, DBS frequency also has been shown to play a
115 key role in altering TRD symptoms [4–6,47]. However, how different LHb DBS
116 parameters, especially stimulation frequencies, alter neural signals or neural
117 biomarkers in TRD patients remains unknown.

118 Here, to close the above gaps, we conducted LHb DBS on one TRD patient where
119 we evaluated the patient’s symptoms and concurrently collected daily LHb LFP
120 signals during the entire 41-week long treatment process (Figure 1A). With this
121 unique dataset and by using machine learning techniques, we identified a clinically-
122 viable neural biomarker from spectral and temporal LHb features that (1) accurately
123 classified high and low depression symptom severity states; (2) significantly tracked
124 the temporal dynamics of weekly (slower) and daily (faster) depression symptom
125 variations during the DBS treatment; (3) reflected the depression symptom changes


126 in response to DBS frequency alterations. Together, our results have implications for
127 identifying clinically-viable neural biomarkers to facilitate future LHB aDBS
128 developments for treating TRD.

129 **2. Materials and Methods**

130 **2.1 Participant**

131 This study included a male TRD patient aged 36-40 years old (see Note S1 for detailed
132 patient medical information) participating in a clinical trial of LHB DBS treatment
133 starting in October 2021. The patient provided informed consent for participation in
134 the clinical trial. This study received approval from the Ethics Committee of Zhejiang
135 University School of Medicine Second Affiliated Hospital (protocol number
136 20210218). It was registered at www.clinicaltrials.gov (NCT05716555), where
137 detailed information regarding the inclusion and exclusion criteria can be accessed.

138 At the beginning of the clinical trial, two independent psychiatrists evaluated the
139 patient's psychotic symptoms using the 17-item Hamilton Depression Rating Scale
140 (HAMD), the Montgomery Asberg Depression Scale (MADRS), and the Hamilton
141 Anxiety Rating Scale (HAMA) as baseline assessments. In addition to the psychiatric
142 assessments, the patient underwent a comprehensive physical examination, various
143 mental scale assessments, and a magnetic resonance imaging (MRI) examination. We
144 carefully ensured that other psychiatric diagnoses outlined in the Diagnostic and
145 Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) were excluded.



146

147 **Figure 1.** Study framework and experiment design. (A) During the Lhb DBS treatment of one
 148 TRD patient, we used weekly clinical ratings and daily self-reports to evaluate the symptom
 149 variations, where we simultaneously collected daily LFP signals from Lhb. Using machine
 150 learning models, we identified a neural biomarker that classified high and low depression
 151 symptom states during the DBS treatment. Using data not used in neural biomarker
 152 identification, we evaluated the neural biomarker in terms of 1) simultaneously tracking the
 153 temporal dynamics of weekly slow and daily fast variations of depression symptoms; 2)
 154 reflecting symptom changes when DBS frequencies were altered. (B) MRI visualization
 155 showing the DBS lead placement within the patient's Lhb. The shaded blue area indicates the
 156 volume of tissue activated (VTA) by the DBS. (C) Temporal dynamics and spectrum of
 157 example epochs of LFP signals after preprocessing. (D) Lhb DBS Treatment Timeline. The
 158 entire treatment process consisted of six stages. LFP signal collection began after the
 159 activation of 1 Hz stimulation.

160 2.2 Surgical procedure

161 A standard DBS implantation procedure was employed. Bilateral quadripolar
 162 electrodes (1200-40, SceneRay, Suzhou, China) were surgically implanted in the Lhb

163 under local anesthesia (Figure 1B). The DBS electrodes had a diameter of 1.27 mm
164 and a lead length of 400 mm. Each electrode's four contacts measured 1.5 mm in
165 length with a spacing of 0.5 mm. The LHb targeting was guided by preoperative MRI
166 sequences. After confirming the absence of stimulation side effects through
167 intraoperative testing, an implantable pulse generator (SR1101, SceneRay) was
168 placed under general anesthesia. The DBS device was also capable of recording and
169 wireless transmitting LFP signals (Figure 1C).

170 **2.3 DBS treatment process and symptom evaluations**

171 During the bilateral DBS treatment process, we made multiple adjustments to the
172 stimulation parameters to achieve the best therapeutic effect. We divided the treatment
173 process into six stages based on the alterations of stimulation parameters (Figure 1D):
174 1) the "Preop" stage, the time before the DBS electrode implantation; 2) the "Off-1"
175 stage, patient recovery with DBS turned off; 3) the "1 Hz" stage, activation of 1 Hz
176 stimulation; 4) the "Off-2" stage, DBS turned off because of unnoticed power off; 5)
177 the "20 Hz" stage, re-activation of 20 Hz stimulation; 6) the "130 Hz" stage,
178 activation of 130 Hz stimulation. More details can be found in Note S2. The entire
179 duration of DBS treatment spanned 41 weeks (starting from DBS electrode
180 implantation).

181 The efficacy of DBS treatment was evaluated from two perspectives: clinician
182 evaluation and self evaluation. For clinician evaluation, a psychologist blinded to the
183 current stimulation parameters and their adjustments evaluated the patient's
184 depression and anxiety symptoms on a weekly basis using standardized rating scales
185 (HAM-D, MADRS, HAMA). Response is defined as a 50% or greater improvement

186 on the HAMD score from the pre-treatment baseline. Remission is defined as
187 achieving a HAMD score of 7 or less. The psychologist also evaluated the patient's
188 emotional blunting and cognitive functioning during the treatment (see Note S3). For
189 self evaluation, the patient used the Visual Analogue Scale (VAS) for depression
190 (VAS-D) and anxiety (VAS-A) to self-report the symptom severity. Self-reported
191 VASA and VAS-D had been used to assess the rapid effects of antidepressants [48].
192 To facilitate daily data collection, we established an online questionnaire system
193 where the patient could conveniently complete the self-reports via the smartphone or
194 computer.

195 **2.4 LFP signal recording, signal processing, and feature** 196 **extraction**

197 After activating the 1 Hz stimulation, we collected daily LFP signals (30 minutes per
198 day) concurrent with daily self-reported VAS-D and VAS-A (details in section 2.3).
199 LFP signals were recorded at a sampling rate of 1000 Hz. Notably, stimulation was
200 deactivated during the signal acquisition process. We reconstructed the electrode
201 positions using MRI and selected two contacts in the left hemisphere for bipolar
202 recording of a single LFP channel. The patient was instructed to attempt daily LFP
203 recording and VAS-D/VAS-A reporting. Throughout the entire 41-week (287-day)
204 treatment, the patient was able to activate LFP recording and report VAS-D and VAS-
205 A on 122 days distributed across 26 weeks. Therefore, the subsequent analyses
206 focused on the LFP signals, VAS-D, and VAS-A scores recorded from these 122 days,
207 and the HAMD, MADRS, and HAMA scores recorded for the 26 weeks.

208 Custom MATLAB scripts (MathWorks Inc., Natick, MA, USA) were used to
209 preprocess the LFP signals. The LFP signals were first band-pass filtered from 1 to
210 30 Hz using a Butterworth filter of order 12 to avoid the noise observed in higher
211 frequency bands. Then, we divided the daily 30-minute LFP signals into 10-second
212 epochs with a 50% overlap. Next, we used a standard procedure (details in Note S4)
213 to remove bad epochs from daily LFP signals (example temporal traces and spectrum
214 of preprocessed LFP epochs were shown in Figure 1C).

215 For each remaining LFP epoch, we computed its spectral domain (SD) and
216 temporal domain (TD) features. SD features included PSD of the four bands (δ (1-4
217 Hz), θ (4-8 Hz), α (8-12 Hz), and β (12-30 Hz)) and phase-amplitude coupling (PAC)
218 for six specific pairs of coupling. TD features included fourteen temporal domain
219 features used in previous study [49], e.g., Hjorth mobility, singular value
220 decomposition (SVD) Fisher information, Hurst exponent, etc. These features capture
221 the temporal properties of LFP from probabilistic distribution and information theory
222 perspectives and have been widely used in brain signal analyses [50,51]. As a result,
223 we obtained 24 features, comprising 10 SD features and 14 TD features for each LFP
224 epoch. Details of these 24 features are included in Table S1 and Note S4. Finally, we
225 averaged each feature across LFP epochs within the same day and obtained a single
226 averaged 24-dimensional LFP feature vector. Our subsequent analyses were based on
227 the daily LFP features as computed above.

228 **2.5 Identification of neural biomarker**

229 We first conducted Spearman's rank correlation analyses between LFP features and
230 symptoms. For each day, we correlated each daily LFP feature with the daily VAS-D

231 and VAS-A self-reports. For each week, we computed the average of LFP features
232 across the days that belonged to this week, resulting in weekly LFP features; we then
233 correlated each weekly LFP feature with the weekly clinical evaluation scales HAMD,
234 HAMA, and MADRS. Bonferroni correction was used to adjust for multiple
235 comparisons.

236 Next, we used a data-driven method to identify an LHb neural biomarker of
237 depression symptoms, where we built a machine learning model to use LFP features
238 to classify high and low depression symptom states.

239 First, we defined the high and low depression symptom states of the patient by k-
240 means clustering the weekly depression scales HAMD and MADRS similar to prior
241 work [17]. Among the total 26 weeks (122 days) of LFP data, 7 weeks (29 days) of
242 LFP data belonged to the low depression symptom state (labeled 0), 4 weeks (22 days)
243 of LFP data belonged to the high depression symptom state (labeled 1). The remaining
244 15 weeks (71 days) were unlabeled and used as test data for subsequent biomarker
245 tracking evaluation (see next section).

246 Second, based on the labeled data, we built a machine learning model to use the
247 LFP features to classify high and low depression symptom states. We constructed six
248 machine learning models: logistic regression (LR), multilayer perceptron (MLP),
249 adaptive boosting (AdaBoost), support vector machine (SVM), random forest (RF),
250 and linear discriminant analysis (LDA). We trained and tested these models using 5-
251 fold cross-validations that were repeated 200 times, where we computed the averaged
252 cross-validated classification accuracy, specificity, sensitivity, F1 score, and Receiver
253 Operating Characteristic (ROC) Area Under the Curve (AUC) score as the

254 performance metrics. The model with the highest accuracy was selected for further
255 analysis.

256 Third, the chosen model was retrained with all labeled data, leading to a “neural
257 biomarker model”. This model takes the LFP feature as input and outputs the decision
258 variable as the neural biomarker value (e.g., in the LR model, the decision variable
259 was computed from the decision probability via the inverse sigmoid function). This
260 allows us to compute a neural biomarker value for any given LFP feature. Higher
261 neural biomarker values indicate more severe depression symptoms.

262 In essence, our identified neural biomarker aggregates spectral and temporal
263 domain features from the LHb LFP signal to classify high and low depression states
264 during DBS treatment.

265 **2.6 Evaluation of the neural biomarker**


266 We evaluated the identified neural biomarker in terms of (1) tracking the temporal
267 dynamics of weekly symptom variations; (2) tracking the temporal dynamics of daily
268 symptom variations; (3) reflecting changes in symptom variations induced by DBS
269 frequency alterations.

270 First, we investigated tracking the temporal dynamics of weekly depression and
271 anxiety symptom scales that were not used in neural biomarker identification. We
272 took the daily LFP features as inputs to the neural biomarker model and computed the
273 output daily neural biomarkers. We then averaged the daily neural biomarkers
274 belonging to the same week to compute the weekly neural biomarkers. We next
275 correlated the weekly neural biomarker values with the weekly HAMD, MADRS, and
276 HAMA scores, respectively, using Spearman’s rank correlation analysis with

277 explained variance (EV) as an estimation. We further analyzed the temporal dynamics
278 in the neural biomarker and symptoms, using the dynamic time warping (DTW)
279 distance [52] to measure the temporal tracking ability of the neural biomarker. Both
280 the neural biomarker values and the symptom scales were normalized to a range of 0
281 to 1. We used a size three Sakoe–Chiba warping window in the DTW analysis
282 following prior work [17,53]. A smaller DTW distance represents better temporal
283 tracking. To determine the significance of the computed DTW distance, we randomly
284 shuffled the temporal sequence of the neural biomarker 10,000 times and used the
285 corresponding shuffled DTW distances as the null hypothesis distribution for
286 computing the *P* value.

287 Second, we investigated tracking the temporal dynamics of the daily VAS-D and
288 VAS-A self-reports, which were also not used in neural biomarker identification.
289 Similar to the weekly case, daily LFP features were used to generate daily neural
290 biomarkers, which were then correlated with daily VAS-D and VAS-A reports. DTW
291 was again used to assess the temporal tracking of daily depression symptom variations.

292 Third, we qualitatively compared trends in weekly neural biomarkers and
293 depression ratings across three DBS frequency alterations (1 Hz to Off-2, Off-2 to 20
294 Hz, 20 Hz to 130 Hz). We used the two-sided Wilcoxon rank-sum test to check whether
295 there was a significant difference between the two stages before and after alteration.
296 We also averaged the neural biomarker values and depression ratings across five time
297 periods for each case: 1) from the beginning of this stage to two weeks before the
298 alteration week; 2) during the week before the alteration week; 3) during the alteration
299 week; 4) during one week after the alteration week; 5) averaged from two weeks after
300 the alteration week to the end of this stage.



301
 302 **Figure 2.** Changes of weekly and daily symptom scores during the Lhb DBS treatment and
 303 their correlations with LFP temporal and spectral domain features. (A) Changes of weekly
 304 clinical ratings during the treatment. The vertical dashed lines represent different treatment
 305 stages indicated by the x-axis labels. (B) Changes of daily self-reports during the treatment.
 306 The vertical dashed lines represent different treatment stages indicated by the x-axis labels. (C)
 307 Heatmap of the correlation coefficients. Each cell shows the correlation coefficient (CC)
 308 value between one LFP feature (y-axis) and one symptom score (x-axis), and cells marked with *
 309 indicate the coefficients that are significantly different from zero (Bonferroni corrected $p < 0.05$).
 310 (D) Positive and negative correlation examples with the weekly HAM-D score and daily VAS-
 311 D score as shown by the yellow boxes in (C).

312 3. Results

313 3.1 Lhb DBS improved the patient's clinical symptoms, which 314 were significantly correlated with Lhb LFP features

315 We first examined the TRD patient's symptom changes throughout the Lhb DBS
 316 treatment process. At the beginning of treatment, the patient's baseline HAM-D score


317 was 20, MADRS score was 25, and HAMA score was 16. In terms of the weekly
318 clinical ratings (Figure 2A), the patient responded at week 14 (HAMD score dropped
319 to 10; MADRS score dropped to 19; HAMA score dropped to 8) and achieved
320 remission by the end of the 41-week treatment (HAMD score was 7; MADRS score
321 was 9; HAMA score was 6). The daily self-reports followed a similar decreasing trend
322 (Figure 2B). Such a consistent trend was confirmed by the strong positive correlation
323 between the daily self-reports and weekly clinical ratings (Spearman's $\rho > 0.5$, $P <$
324 0.05 for all pair-wise correlations; see Table S2 and Figure S1 for details). Besides
325 alleviating the symptoms based on the weekly clinical ratings and daily self-reports,
326 we also found improvement in emotional blunting and cognitive functioning (Note
327 S3 and Tables S3-S5).

328 During the LHb DBS treatment process, we recorded daily LHb LFP signals.
329 Therefore, we investigated how the LFP features correlated with the patient's
330 symptom changes. We found that many of the temporal and spectral domain LHb LFP
331 features were significantly correlated with the weekly clinical ratings and daily self-
332 reports (Figure 2C). For example, Hurst exponent exhibited the strong correlations
333 with both weekly HAMD scores (Figure 2D, Spearman's $\rho = -0.85$, Bonferroni
334 corrected $P = 4.7 \times 10^{-6}$) and daily VAS-D scores (Figure 2D, Spearman's $\rho =$
335 -0.76 , Bonferroni corrected $P = 3.8 \times 10^{-22}$). These results show that LHb LFP
336 temporal and spectral domain features were strongly correlated with weekly and daily
337 depression symptom scores, indicating that it is feasible to identify an LHb neural
338 biomarker of depression symptoms from the LFP temporal and spectral domain
339 features.

340 **3.2 Accurate classification of high and low depression symptom**
341 **severity states led to the identification of an LHb neural**
342 **biomarker**

343 We next used the LFP temporal and spectral features to identify a neural biomarker
344 that can classify high and low depression symptom severity states. We started by
345 defining a state of high symptom severity and a state of low symptom severity via
346 clustering the weekly depression scales HAMD and MADRS (Figure 3A). The high
347 symptom state (7 weeks) had an average HAMD score of 12.8 and an average
348 MADRS score of 22.5, while the low symptom state (4 weeks) had an average HAMD
349 score of 6.3 and an average MADRS score of 9.0. We then used LFP temporal domain
350 and spectral domain features from these 11 weeks to classify the high and low
351 symptom severity states via six machine learning models in cross-validation. Among
352 these six models, the LR model performed better than other more complicated models
353 (Figure 3B and table S6). Specifically, for the LR model, the cross-validated
354 classification accuracy was 0.973 ± 0.002 (Mean \pm SEM), the specificity was
355 0.961 ± 0.003 , the sensitivity was 0.988 ± 0.002 , the F1-score was 0.970 ± 0.002 ,
356 and the AUC score was 0.974 ± 0.001 , which were all significantly higher than
357 other models (Wilcoxon rank sum test, Bonferroni corrected $P < 0.05$ for all
358 comparisons), suggesting that the LR model was best suited for classifying the
359 collected data. We thus selected the LR model for further analysis. Then, we retrained
360 the LR model using all labeled data, resulting in the neural biomarker model. The
361 neural biomarker model takes the LFP features as input and outputs the model

362 decision value as the identified neural biomarker, with higher values indicating worse
 363 depression symptoms.




364
 365 **Figure 3.** Accurate classification of high and low depression symptom severity states by the
 366 identified neural biomarker. (A) Clustering of depression symptom severity states. We clustered
 367 the HAMD and MADRS scores to obtain two distinct symptom states: a high depression
 368 symptom severity state (shaded in red) and a low depression symptom severity state (shaded in
 369 blue). Each point represents data of a week. The average HAMD and MADRS scores of the
 370 two clusters are also indicated in the figure. (B) Classification performance of different
 371 classifiers. The bar represents mean and the whiskers represent the 95% confidence interval.
 372 Six classification models (different colors) were compared in terms of five performance
 373 matrices (different x-axis groups): accuracy, specificity, sensitivity, F1-Score and AUC. The
 374 best model was indicated by a yellow star for each metric. Classification model names and
 375 abbreviations: logistic regression (LR), multilayer perceptron (MLP), adaptive boosting
 376 (AdaBoost), support vector machine (SVM), random forest (RF), and linear discriminant
 377 analysis (LDA). (C) Classification accuracy of individual features and all LFP features by the
 378 logistic regression model. The individual SD features are in green, and their indices are ordered
 379 based on classification accuracy. The individual TD features are in blue, and their indices are
 380 ordered by classification accuracy. The combination of all LFP features is in brown. The best
 381 individual feature was indicated by a yellow star for each domain. (D) The absolute coefficients
 382 of each feature in the logistic regression model trained with all LFP features. The individual
 383 feature indices are the same as in (C).

384 We further investigated how different features contributed to identifying the
385 neural biomarker by performing separate classifications for each feature (Figure 3C).
386 The best temporal domain feature was the Hurst exponent, with a cross-validated
387 classification accuracy of 0.932. While the best spectral domain feature was the PSD
388 of the β band, with an average accuracy of 0.803. Overall, temporal domain features
389 (average accuracy: 0.781) outperformed spectral domain features (average accuracy:
390 0.705). Notably, combining all the LFP features yielded superior performance
391 compared to individual features. Consistently, by investigating the logistic regression
392 coefficients of the neural biomarker model (Figure 3D), we found that the features
393 with better classification accuracy also had larger coefficients in the neural biomarker
394 model. These results show that the temporal domain and spectral domain features had
395 supplementary information that both contributed to the identification of the neural
396 biomarker, with temporal features having a stronger influence.

397 **3.3 The identified neural biomarker simultaneously tracked the** 398 **temporal dynamics of weekly and daily depression symptom** 399 **variations during LHb DBS treatment**


400 After identifying the neural biomarker of depression symptoms, we evaluated its
401 ability to track the temporal dynamics of slow (weekly) and fast (daily) depression
402 symptom variations during the LHb DBS treatment. For slow weekly variations, we
403 used the identified neural biomarker model to compute weekly neural biomarker
404 values (see Methods section 2.6 for details). We used the weekly neural biomarker
405 values to predict the associated weekly clinical ratings, where we strictly excluded
406 the weekly data that were used to identify the neural biomarker (i.e., the prediction



407

408 **Figure 4.** Accurate tracking the temporal dynamics of weekly depression symptom variations
 409 by the identified neural biomarker. (A) Left: correlation between the identified neural
 410 biomarker values and the weekly HAMD scores unseen in neural biomarker identification. EV:
 411 Explained variance. Middle: neural biomarker tracking of the weekly HAMD score dynamics
 412 over time. Right: the DTW distance analysis result for evaluating the significance of tracking
 413 in the middle panel. Smaller DTW distance represents better tracking. Note that we normalized
 414 both the neural biomarker values and the symptom scales to a range of 0 to 1 using min-max
 415 normalization for better visualization. (B) same as (A) but for the weekly MADRS scores. (C)
 416 same as (A) but for the weekly HAMA scores.

417 was based on new unseen data not used in training the neural biomarker model). We
 418 found that the weekly neural biomarker values significantly predicted the HAMD
 419 scores (Figure 4A, $EV=0.74$, $P = 1.1 \times 10^{-5}$). Further, considering the temporal
 420 dynamics in detail by using the DTW distance analysis (see Methods section 2.6), we
 421 found that the weekly neural biomarker significantly tracked the temporal dynamics
 422 of weekly HAMD score variations (random shuffle $P = 0.00001$). Consistently, the
 423 weekly neural biomarker values significantly predicted the MADRS scores (Figure
 424 4B, $EV=0.34$, $P = 0.039$), and tracked the temporal dynamics in the DTW distance
 425 analysis with marginally significant statistics (random shuffle $P = 0.1079$). Converse-



426
427 **Figure 5.** Accurate tracking the temporal dynamics of daily depression symptom variations by
428 the identified neural biomarker. (A) Left: correlation between the identified neural biomarker
429 values and the daily VAS-D scores unseen in neural biomarker identification. EV: Explained
430 variance. Middle: neural biomarker tracking of the daily VAS-D score dynamics over time.
431 Right: the DTW distance analysis result for evaluating the significance of tracking in the middle
432 panel. Smaller DTW distance represents better tracking. (B) same as (A) but for the daily VAS-
433 A scores.

434 ly, the weekly neural biomarker values did not predict the HAMA scores (Figure 4C,
435 $EV=0.03$, $P = 5.2 \times 10^{-1}$) or tracked the temporal dynamics (random shuffle $P =$
436 0.5865).


437 For fast daily variations, we used the identified neural biomarker model to
438 compute daily neural biomarker values and used the daily neural biomarker values to
439 predict the associated daily self-reports (again, data not used in training the neural
440 biomarker model). We found that the daily neural biomarker values significantly
441 predicted the VAS-D scores (Figure 5A, $EV=0.63$, $P = 1.3 \times 10^{-27}$) and showed
442 significant tracking of VAS-D dynamics (random shuffle $P = 0.0001$). By contrast,
443 while the daily neural biomarker values predicted the VAS-A scores (Figure 5B,
444 $EV=0.51$, $P = 5.3 \times 10^{-16}$) but the daily neural biomarker did not track VAS-A
445 dynamics (random shuffle $P = 1.00$).

446 In summary, the results show that the identified neural biomarker significantly
447 tracked the temporal dynamics of both weekly and daily variations in depression

448 symptoms during the LHB DBS treatment and specifically tracked depression
449 symptoms rather than anxiety symptoms.

450 **3.4 The identified neural biomarker reflected changes of** 451 **depression symptoms in response to DBS parameter** 452 **alterations**

453 A useful neural biomarker for DBS also needs to reflect the effect of different DBS
454 parameters. We thus finally evaluated if the identified neural biomarker could reflect
455 changes in depression symptoms in response to DBS parameter alterations. We
456 applied three different DBS frequencies during the treatment: 1 Hz, 20 Hz, and 130
457 Hz. For the DBS alteration from 1 Hz to stimulation off (Off-2, the DBS device shut
458 down due to unnoticed power off), there was a trend of increasing for the neural
459 biomarker, HAMD, and MADRS while the statistical tests were not significant due
460 the limited sample size (Figure 6A, 1Hz v.s. stimulation off, normalized mean \pm s.e.m.,
461 neural biomarker: 0.912 ± 0.055 v.s. 0.956 ± 0.026 , $P=0.35$; HAMD: 0.562 ± 0.062
462 v.s. 0.688 ± 0.036 , $P=0.16$; MADRS: 0.656 ± 0.031 v.s. 0.734 ± 0.053 , $P=0.35$),
463 which indicated a rebound trend of depression symptoms due to the disruption of DBS
464 treatment. For the DBS alteration from stimulation off (Off-2) to 20 Hz stimulation
465 (Figure 6B), the neural biomarker, HAMD, and MADRS consistently decreased
466 (Figure 6B, stimulation off v.s. 20 Hz, neural biomarker: 0.905 ± 0.095 v.s. $0.545 \pm$
467 0.059 , $P=0.04$; HAMD: 0.875 ± 0.125 v.s. 0.375 ± 0.072 , $P=0.05$; MADRS: 0.875
468 ± 0.000 v.s. 0.606 ± 0.061 , $P=0.08$). Specifically, the neural biomarker, HAMD and
469 MADRS scores all decreased at the week of DBS frequency alteration, further
470 decreased one week after the alteration and continued to decrease with more obvious



471 **Figure 6.** The consistent trend between the neural biomarker and the depression symptom
 472 changes when DBS frequencies were altered. (A) DBS frequency was altered from 1 Hz to Off-
 473 2. Top: comparison of the values of the biomarker, HAMD scores and MADRS scores between the
 474 1Hz stage and Off-2 stage. Two-sided Wilcoxon rank-sum test was used for significance
 475 test. Row two: changes in the identified neural biomarker time-locked to the DBS frequency
 476 alteration week (vertical dashed line). Row three: changes in HAMD time-locked to the DBS
 477 frequency alteration week. Bottom: changes in MADRS time-locked to the DBS frequency
 478 alteration week. (B) same as (A) but for DBS frequency alteration from Off-2 to 20 Hz. (C)
 479 same as (A) but for DBS frequency alteration from 20 Hz to 130 Hz.
 480

481 changes after week two. For the DBS alteration from 20 Hz to 130 Hz stimulation
 482 (Figure 6C), the neural biomarker, HAMD, and MADRS also consistently decreased
 483 (Figure 6C, 20 Hz v.s. 130 Hz, neural biomarker: 0.524 ± 0.060 v.s. 0.088 ± 0.029 ,
 484 $P=0.001$; HAMD: 0.323 ± 0.054 v.s. 0.042 ± 0.026 , $P=0.004$; MADRS: $0.573 \pm$
 485 0.056 v.s. 0.062 ± 0.016 , $P=0.001$). More specifically, the neural biomarker, HAMD
 486 and MADRS scores already showed a trend of decreasing before the DBS frequency
 487 alteration, and the alleviated symptoms stayed relatively stable during the alteration
 488 week, at week one after the alteration, and the same stable trend continued after week
 489 two. The results suggested that the 1 Hz DBS did not induce an obvious change in
 490 depression symptoms, while the 20 Hz and 130 Hz DBS had more meaningful effects.

491 The results further demonstrated that the identified neural biomarker indeed reflected
492 the different change patterns in depression symptoms when the DBS frequencies were
493 altered.

494 **4. Discussion**

495 **4.1 A data-driven LHb neural biomarker for tracking slow and** 496 **fast depression symptom variations during DBS treatment**

497 A mechanism-driven neural biomarker for depression is currently lacking mainly
498 because the neural circuitry underlying depression has not been clearly delineated
499 [54]. Therefore, current neural biomarkers of depression symptoms for tracking DBS
500 effects have largely used data-driven machine learning methods to map LFP features
501 to depression symptom ratings [17,31,32]. The usefulness of data-driven neural
502 biomarkers critically depends on the data used to identify the neural biomarker. For
503 example, a recent work [31] focused on a cingulate neural biomarker that was trained
504 with and accordingly predicted longer-term (on the time scale of weeks) clinical
505 ratings. On the other hand, another recent work [17] only trained and tested a neural
506 biomarker with shorter-term (on the time scale of minutes) self-reports. Our work is
507 unique in that while we identified our LHb neural biomarker based on weekly clinical
508 ratings, we demonstrated that the neural biomarker predicted not only weekly clinical
509 ratings (data not used in identification) but also daily self-reports (data again not used
510 in identification). The results suggested that our LHb neural biomarker could track
511 the temporal dynamics of both slow and fast depression symptom variations, which
512 was useful for developing new aDBS strategies that are robust across different time

513 scales. It is worth noting that our LHb neural biomarker specifically tracked the
514 temporal dynamics of weekly and daily depression symptom scores but not the
515 anxiety symptom scores. It suggests that despite the overlapping of depression-related
516 and anxiety-related brain networks [55], LHb neural activity is mainly related to
517 depression, which is supported by prior animal studies [21,22].

518 Both population-level and personalized neural biomarkers of depression
519 symptoms have been identified for tracking DBS effects. Population-level neural
520 biomarkers are derived from data collected from several patients and have the benefits
521 of being directly applicable to a new patient and robust interpretability of the neural
522 biomarker's biophysical mechanism across patients [31]. By contrast, personalized
523 neural biomarkers are derived from data collected from an individual patient, which
524 is more powerful in capturing the unique characteristics of depression symptoms in
525 each patient, especially given the large inter-individual variability in depression-
526 related brain networks [56]. With the emerging capability of recording more data
527 within a single patient using mobile devices, personalized neural biomarker models
528 can be more accurate in tracking the temporal dynamics of depression symptom
529 variations. With such trends, a personalized neural biomarker has been identified and
530 used for realizing aDBS targeting VC/VS [17]. Our study identified a personalized
531 neural biomarker that achieved accurate classification and tracking of depression
532 symptom variations during the DBS treatment targeting LHb, confirming the
533 usefulness of personalization. Nevertheless, population-level and personalized neural
534 biomarkers can complement each other. For example, one can leverage a large amount
535 of population data to train an interpretable population-level neural biomarker model,

536 followed by fine-tuning with personalized data to further improve its accuracy, which
537 is an important future research direction.

538 **4.2 Importance of fusing LFP temporal domain and spectral** 539 **domain features to identify the neural biomarker**

540 Previous studies have exclusively used LFP spectral domain features to identify the
541 neural biomarker for depression [17,31,32]. By contrast, we found that both the LFP
542 temporal domain and spectral domain features contributed to our neural biomarker
543 and that the temporal domain features contributed relatively more than the spectral
544 domain features. The main contributing temporal domain feature was the Hurst
545 exponent. The Hurst exponent measures “long-term memory” in temporal dynamics
546 and is associated with the autocorrelation of a time series [57]. Our results suggest
547 that the LHb LFP signal’s auto-correlations might change during DBS. The main
548 contributing (top 2) spectral domain feature was the PSD of the β band. The LHb β
549 band oscillation was also found to correlate with depression symptoms before DBS
550 treatment in a previous study [27]. These findings highlight the significance of the β
551 band oscillations in LHb as related to depression. Both the Hurst exponent and the β
552 band oscillation features reflect the abnormal synchronization of LHb neural
553 ensembles underlying depression and might be related to the abnormal burst spiking
554 phenomena of LHb neurons found in rodents exhibiting depression-like behaviors
555 [21,22]. The mechanism underlying the contributing LFP temporal domain and
556 spectral domain features requires further investigation by future research.

557 **4.3 DBS frequency differentially modulates the depression** 558 **symptom and neural biomarker**

559 Prior studies have shown that DBS frequency can significantly influence the treatment
560 efficacy for TRD, e.g., high-frequency DBS has generally yielded better treatment
561 outcomes than low-frequency DBS [23,58,59]. Consistently, we discovered that a
562 very low DBS frequency of 1 Hz was not effective in alleviating the depression
563 symptoms in our patient, but higher frequencies of 20 Hz and 130 Hz were more
564 effective. Beyond the depression symptom ratings, we additionally found that the
565 neural biomarker was also consistently modulated by the different DBS frequencies.
566 DBS frequency might influence the release of neurotransmitters in depression-
567 targeted pathways [60], thus modulating the neural biomarker and the depression
568 symptoms. However, similar to other DBS targets, the optimal DBS frequency at LHb
569 is still also an open question that requires further research.

570 **5. Limitations**

571 Our study has several limitations. First, our study had a limited sample size (n-of-1);
572 further studies with more patients are needed to confirm our findings on LHb neural
573 biomarkers. Second, despite its powerful classification and tracking performance, our
574 neural biomarker was identified using only one channel of LFP signals. Incorporating
575 multi-channel LFP signals in future studies would allow for finding neural biomarkers
576 with even better performance and a more comprehensive understanding of the neural
577 mechanism underlying neural biomarker identification. Third, due to the high-
578 frequency recording noise of our DBS device, we filtered the LFP signal below 30 Hz
579 to ensure noise rejection. Future work with better recording capability should

580 investigate how higher-frequency LFP temporal and spectral domain features
581 contribute to the identification of neural biomarkers. Finally, our LFP signals were
582 recorded with the stimulation temporarily turned OFF to eliminate stimulation
583 artifacts. While this approach ensured clean LFP signals, it is important to consider
584 using LFP signals during stimulation to identify neural biomarkers, but this requires
585 high-performance stimulation artifact removal, which remains challenging [61].

586 **6. Conclusion**

587 One patient with TRD reached remission after 41 weeks of LHb DBS treatment. With
588 a unique data collection of concurrent daily and weekly depression symptom scores
589 and LHb LFP signals during the entire treatment process, we used machine learning
590 to identify an LHb neural biomarker of depression symptoms. We demonstrated that
591 our LHb neural biomarker accurately classified high and low depression symptom
592 severity states, simultaneously tracked the temporal dynamics of weekly (slow) and
593 daily (fast) depression symptom variations during the DBS treatment process, and
594 reflected the depression symptom changes in response to DBS frequency alterations.
595 Our methods and results hold promise in identifying clinically-viable neural
596 biomarkers to facilitate future adaptive DBS developments for treating TRD.

597

598 **Data availability**

599 The data supporting this study's findings are available from the corresponding author
600 upon reasonable request.

501 **Funding**

502 This work was supported in part by the National Natural Science Foundation of China
503 under Grants 62336007 and 62306269, in part by the Zhejiang Provincial Natural
504 Science Foundation of China under Grant LD24H090001, in part by the Key R&D
505 Program of Zhejiang under Grant 2022C03011, in part by the Starry Night Science
506 Fund of Zhejiang University Shanghai Institute for Advanced Study under Grant SN-
507 ZJU-SIAS-002, in part by the Non-profit Central Research Institute Fund of Chinese
508 Academy of Medical Sciences under Grant 2023-PT310-01, and in part by the
509 Fundamental Research Funds for the Central Universities under Grant 226-2024-
510 00127.

511 **Author Contributions**

512 Shi Liu: Methodology, Software, Formal analysis, Writing - Original Draft,
513 Visualization. Yu Qi: Investigation, Resources. Shaohua Hu: Conceptualization,
514 Resources. Ning Wei: Resources, Data Curation, Writing - Original Draft. Jianmin
515 Zhang: Conceptualization, Resources. Junming Zhu: Conceptualization, Resources.
516 Hemmings Wu: Conceptualization, Investigation. Hailan Hu: Conceptualization.
517 Yuxiao Yang: Conceptualization, Supervision, Methodology, Writing - Review &
518 Editing, Funding acquisition. Yueming Wang: Conceptualization, Supervision,
519 Project administration, Funding acquisition, Writing - Review & Editing. All authors
520 revised and approved the final version of the manuscript.

521 **Conflict of Interest**

522 There are no financial conflicts of interest to disclose.

523 References





- 524 [1] Organization WH, others. Depression and other common mental
525 disorders: global health estimates. World Health Organization; 2017.
- 526 [2] Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al.
527 Major depressive disorder. *Nat Rev Dis Primer* 2016;2:16065.
528 <https://doi.org/10.1038/nrdp.2016.65>.
- 529 [3] Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, et al.
530 Technology of deep brain stimulation: current status and future
531 directions. *Nat Rev Neurol* 2021;17:75–87.
532 <https://doi.org/10.1038/s41582-020-00426-z>.
- 533 [4] Dandekar MP, Fenoy AJ, Carvalho AF, Soares JC, Quevedo J. Deep
534 brain stimulation for treatment-resistant depression: an integrative
535 review of preclinical and clinical findings and translational implications.
536 *Mol Psychiatry* 2018;23:1094–112. <https://doi.org/10.1038/mp.2018.2>.
- 537 [5] Figeo M, Riva-Posse P, Choi KS, Bederson L, Mayberg HS, Kopell BH.
538 Deep Brain Stimulation for Depression. *Neurotherapeutics*
539 2022;19:1229–45. <https://doi.org/10.1007/s13311-022-01270-3>.
- 540 [6] Johnson KA, Okun MS, Scangos KW, Mayberg HS, de Hemptinne C.
541 Deep brain stimulation for refractory major depressive disorder: a
542 comprehensive review. *Mol Psychiatry* 2024;1–13.
543 <https://doi.org/10.1038/s41380-023-02394-4>.
- 544 [7] Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani
545 C, et al. Deep Brain Stimulation for Treatment-Resistant Depression.
546 *Neuron* 2005;45:651–60. <https://doi.org/10.1016/j.neuron.2005.02.014>.
- 547 [8] Malone DA, Dougherty DD, Rezai AR, Carpenter LL, Friehs GM,
548 Eskandar EN, et al. Deep Brain Stimulation of the Ventral
549 Capsule/Ventral Striatum for Treatment-Resistant Depression. *Biol*
550 *Psychiatry* 2009;65:267–75.
551 <https://doi.org/10.1016/j.biopsych.2008.08.029>.
- 552 [9] Schlaepfer TE, Bewernick BH, Kayser S, Mädler B, Coenen VA. Rapid
553 Effects of Deep Brain Stimulation for Treatment-Resistant Major
554 Depression. *Biol Psychiatry* 2013;73:1204–12.
555 <https://doi.org/10.1016/j.biopsych.2013.01.034>.
- 556 [10] Neumann W-J, Huebl J, Brücke C, Gabriëls L, Bajbouj M, Merkl A, et al.
557 Different patterns of local field potentials from limbic DBS targets in
558 patients with major depressive and obsessive compulsive disorder. *Mol*
559 *Psychiatry* 2014;19:1186–92. <https://doi.org/10.1038/mp.2014.2>.
- 560 [11] Bergfeld IO, Mantione M, Hoogendoorn MLC, Ruhe HG, Notten P, van
561 Laarhoven J, et al. Deep Brain Stimulation of the Ventral Anterior Limb
562 of the Internal Capsule for Treatment-Resistant Depression A
563 Randomized Clinical Trial. *Jama Psychiatry* 2016;73:456–64.
564 <https://doi.org/10.1001/jamapsychiatry.2016.0152>.
- 565 [12] Dougherty DD, Rezai AR, Carpenter LL, Howland RH, Bhati MT,
566 O'Reardon JP, et al. A Randomized Sham-Controlled Trial of Deep Brain
567 Stimulation of the Ventral Capsule/Ventral Striatum for Chronic
568 Treatment-Resistant Depression. *Biol Psychiatry* 2015;78:240–8.
569 <https://doi.org/10.1016/j.biopsych.2014.11.023>.





- 570 [13] Holtzheimer PE, Husain MM, Lisanby SH, Taylor SF, Whitworth LA,
571 McClintock S, et al. Subcallosal cingulate deep brain stimulation for
572 treatment-resistant depression: a multisite, randomised, sham-
573 controlled trial. *Lancet Psychiatry* 2017;4:839–49.
574 [https://doi.org/10.1016/S2215-0366\(17\)30371-1](https://doi.org/10.1016/S2215-0366(17)30371-1).
- 575 [14] Coenen VA, Bewernick BH, Kayser S, Kilian H, Boström J, Greschus S,
576 et al. Superolateral medial forebrain bundle deep brain stimulation in
577 major depression: a gateway trial. *Neuropsychopharmacology*
578 2019;44:1224–32. <https://doi.org/10.1038/s41386-019-0369-9>.
- 579 [15] Raymaekers S, Luyten L, Bervoets C, Gabriëls L, Nuttin B. Deep brain
580 stimulation for treatment-resistant major depressive disorder: a
581 comparison of two targets and long-term follow-up. *Transl Psychiatry*
582 2017;7:e1251–e1251. <https://doi.org/10.1038/tp.2017.66>.
- 583 [16] Guidetti M, Marceglia S, Loh A, Harmsen IE, Meoni S, Foffani G, et al.
584 Clinical perspectives of adaptive deep brain stimulation. *Brain Stimulat*
585 2021;14:1238–47. <https://doi.org/10.1016/j.brs.2021.07.063>.
- 586 [17] Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP,
587 Zamanian H, et al. Closed-loop neuromodulation in an individual with
588 treatment-resistant depression. *Nat Med* 2021;27:1696–700.
589 <https://doi.org/10.1038/s41591-021-01480-w>.
- 590 [18] Hu H, Cui Y, Yang Y. Circuits and functions of the lateral habenula in
591 health and in disease. *Nat Rev Neurosci* 2020;21:277–95.
592 <https://doi.org/10.1038/s41583-020-0292-4>.
- 593 [19] Roman E, Weininger J, Lim B, Roman M, Barry D, Tierney P, et al.
594 Untangling the dorsal diencephalic conduction system: a review of
595 structure and function of the stria medullaris, habenula and fasciculus
596 retroflexus. *Brain Struct Funct* 2020;225:1437–58.
597 <https://doi.org/10.1007/s00429-020-02069-8>.
- 598 [20] Dai D, Li W, Chen A, Gao X-F, Xiong L. Lateral Habenula and Its
599 Potential Roles in Pain and Related Behaviors. *ACS Chem Neurosci*
700 2022;13:1108–18. <https://doi.org/10.1021/acscchemneuro.2c00067>.
- 701 [21] Cui Y, Yang Y, Dong Y, Hu H. Decoding Depression: Insights from Glial
702 and Ketamine Regulation of Neuronal Burst Firing in Lateral Habenula.
703 *Cold Spring Harb Symp Quant Biol* 2018;83:141–50.
704 <https://doi.org/10.1101/sqb.2018.83.036871>.
- 705 [22] Cui Y, Yang Y, Ni Z, Dong Y, Cai G, Foncelle A, et al. Astroglial Kir4.1 in
706 the lateral habenula drives neuronal bursts in depression. *Nature*
707 2018;554:323–7. <https://doi.org/10.1038/nature25752>.
- 708 [23] Sartorius A, Kiening KL, Kirsch P, Gall CC von, Haberkorn U, Unterberg
709 AW, et al. Remission of Major Depression Under Deep Brain Stimulation
710 of the Lateral Habenula in a Therapy-Refractory Patient. *Biol Psychiatry*
711 2010;67:e9–11. <https://doi.org/10.1016/j.biopsych.2009.08.027>.
- 712 [24] Wang Z, Cai X, Qiu R, Yao C, Tian Y, Gong C, et al. Case Report: Lateral
713 Habenula Deep Brain Stimulation for Treatment-Resistant Depression.
714 *Front Psychiatry* 2021;11. <https://doi.org/10.3389/fpsy.2020.616501>.
- 715 [25] Kiening K, Sartorius A. A new translational target for deep brain
716 stimulation to treat depression. *EMBO Mol Med* 2013;5:1151–3.
717 <https://doi.org/10.1002/emmm.201302947>.





- 718 [26] Zhang C, Kim S-G, Li D, Zhang Y, Li Y, Husch A, et al. Habenula deep
719 brain stimulation for refractory bipolar disorder. *Brain Stimulat*
720 2019;12:1298–300. <https://doi.org/10.1016/j.brs.2019.05.010>.
- 721 [27] Zhang C, Zhang Y, Luo H, Xu X, Yuan T, Li D, et al. Bilateral Habenula
722 deep brain stimulation for treatment-resistant depression: clinical
723 findings and electrophysiological features. *Transl Psychiatry* 2022;12:52.
724 <https://doi.org/10.1038/s41398-022-01818-z>.
- 725 [28] Wang Z, Jiang C, Guan L, Zhao L, Fan T, Wang J, et al. Deep brain
726 stimulation of habenula reduces depressive symptoms and modulates
727 brain activities in treatment-resistant depression. *Nat Ment Health* 2024.
728 <https://doi.org/10.1038/s44220-024-00286-2>.
- 729 [29] Vissani M, Isaias IU, Mazzoni A. Deep brain stimulation: a review of the
730 open neural engineering challenges. *J Neural Eng* 2020;17:051002.
731 <https://doi.org/10.1088/1741-2552/abb581>.
- 732 [30] Priori A, Maiorana N, Dini M, Guidetti M, Marceglia S, Ferrucci R.
733 Chapter Six - Adaptive deep brain stimulation (aDBS). In: Moro E,
734 Polosan M, Hamani C, editors. *Int Rev Neurobiol*, vol. 159, Academic
735 Press; 2021, p. 111–27. <https://doi.org/10.1016/bs.irn.2021.06.006>.
- 736 [31] Alagapan S, Choi KS, Heisig S, Riva-Posse P, Crowell A, Tiruvadi V, et
737 al. Cingulate dynamics track depression recovery with deep brain
738 stimulation. *Nature* 2023:1–9. [https://doi.org/10.1038/s41586-023-](https://doi.org/10.1038/s41586-023-06541-3)
739 [06541-3](https://doi.org/10.1038/s41586-023-06541-3).
- 740 [32] Frank AC, Scangos KW, Larson PS, Norbu T, Lee AT, Lee AM.
741 Identification of a personalized intracranial biomarker of depression and
742 response to DBS therapy. *Brain Stimulat* 2021;14:1002–4.
743 <https://doi.org/10.1016/j.brs.2021.06.009>.
- 744 [33] Sonkusare S, Ding Q, Zhang Y, Wang L, Gong H, Mandali A, et al.
745 Power signatures of habenular neuronal signals in patients with bipolar
746 or unipolar depressive disorders correlate with their disease severity.
747 *Transl Psychiatry* 2022;12:1–9. [https://doi.org/10.1038/s41398-022-](https://doi.org/10.1038/s41398-022-01830-3)
748 [01830-3](https://doi.org/10.1038/s41398-022-01830-3).
- 749 [34] Cobb BS, Coryell WH, Cavanaugh J, Keller M, Solomon DA, Endicott J,
750 et al. Seasonal variation of depressive symptoms in unipolar major
751 depressive disorder. *Compr Psychiatry* 2014;55:1891–9.
752 <https://doi.org/10.1016/j.comppsy.2014.07.021>.
- 753 [35] Panaite V, Rottenberg J, Bylsma LM. Daily Affective Dynamics Predict
754 Depression Symptom Trajectories Among Adults with Major and Minor
755 Depression. *Affect Sci* 2020;1:186–98. [https://doi.org/10.1007/s42761-](https://doi.org/10.1007/s42761-020-00014-w)
756 [020-00014-w](https://doi.org/10.1007/s42761-020-00014-w).
- 757 [36] Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y,
758 Mayberg HS, et al. Deep Brain Stimulation for Treatment-Resistant
759 Depression: Follow-Up After 3 to 6 Years. *Am J Psychiatry*
760 2011;168:502–10. <https://doi.org/10.1176/appi.ajp.2010.10081187>.
- 761 [37] Bewernick BH, Kayser S, Sturm V, Schlaepfer TE. Long-Term Effects of
762 Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant
763 Depression: Evidence for Sustained Efficacy.
764 *Neuropsychopharmacology* 2012;37:1975–85.
765 <https://doi.org/10.1038/npp.2012.44>.




- 766 [38] Crowell AL, Riva-Posse P, Holtzheimer PE, Garlow SJ, Kelley ME,
767 Gross RE, et al. Long-Term Outcomes of Subcallosal Cingulate Deep
768 Brain Stimulation for Treatment-Resistant Depression. *Am J Psychiatry*
769 2019;176:949–56. <https://doi.org/10.1176/appi.ajp.2019.18121427>.
- 770 [39] Peeters F, Berkhof J, Delespaul P, Rottenberg J, Nicolson NA. Diurnal
771 mood variation in major depressive disorder. *Emotion* 2006;6:383–91.
772 <https://doi.org/10.1037/1528-3542.6.3.383>.
- 773 [40] Wirz-Justice A. Diurnal variation of depressive symptoms. *Dialogues*
774 *Clin Neurosci* 2008;10:337–43.
775 <https://doi.org/10.31887/DCNS.2008.10.3/awjustice>.
- 776 [41] Scangos KW, Makhoul GS, Sugrue LP, Chang EF, Krystal AD. State-
777 dependent responses to intracranial brain stimulation in a patient with
778 depression. *Nat Med* 2021;27:229–31. <https://doi.org/10.1038/s41591-020-01175-8>.
- 780 [42] Bewernick BH, Kayser S, Gippert SM, Coenen VA, Schlaepfer TE.
781 Acute antidepressant effects of deep brain stimulation – Review and
782 data from sIMFB-stimulation. *Pers Med Psychiatry* 2017;3:1–7.
783 <https://doi.org/10.1016/j.pmip.2017.01.002>.
- 784 [43] Xiao J, Provenza NR, Asfour J, Myers J, Mathura RK, Metzger B, et al.
785 Decoding Depression Severity From Intracranial Neural Activity. *Biol*
786 *Psychiatry* 2023;94:445–53.
787 <https://doi.org/10.1016/j.biopsych.2023.01.020>.
- 788 [44] Sani OG, Yang Y, Lee MB, Dawes HE, Chang EF, Shanечи MM. Mood
789 variations decoded from multi-site intracranial human brain activity. *Nat*
790 *Biotechnol* 2018;36:954–61. <https://doi.org/10.1038/nbt.4200>.
- 791 [45] Kirkby LA, Luongo FJ, Lee MB, Nahum M, Vleet TMV, Rao VR, et al. An
792 Amygdala-Hippocampus Subnetwork that Encodes Variation in Human
793 Mood. *Cell* 2018;175:1688-1700.e14.
794 <https://doi.org/10.1016/j.cell.2018.10.005>.
- 795 [46] Ashkan K, Rogers P, Bergman H, Ughratdar I. Insights into the
796 mechanisms of deep brain stimulation. *Nat Rev Neurol* 2017;13:548–
797 54. <https://doi.org/10.1038/nrneurol.2017.105>.
- 798 [47] Ramasubbu R, Lang S, Kiss ZHT. Dosing of Electrical Parameters in
799 Deep Brain Stimulation (DBS) for Intractable Depression: A Review of
800 Clinical Studies. *Front Psychiatry* 2018;9.
801 <https://doi.org/10.3389/fpsy.2018.00302>.
- 802 [48] Yeung AWK, Wong NSM. The Historical Roots of Visual Analog Scale in
803 Psychology as Revealed by Reference Publication Year Spectroscopy.
804 *Front Hum Neurosci* 2019;13.
805 <https://doi.org/10.3389/fnhum.2019.00086>.
- 806 [49] Schiratti J-B, Le Douget J-E, Le van Quyen M, Essid S, Gramfort A. An
807 ensemble learning approach to detect epileptic seizures from long
808 intracranial EEG recordings. *ICASSP 2018 - 2018 IEEE Int. Conf.*
809 *Acoust. Speech Signal Process. ICASSP, Calgary, Canada: IEEE; 2018.*
810 <https://doi.org/10.1109/ICASSP.2018.8461489>.
- 811 [50] Banville H, Wood SUN, Aimone C, Engemann D-A, Gramfort A. Robust
812 learning from corrupted EEG with dynamic spatial filtering. *NeuroImage*
813 2022;251:118994. <https://doi.org/10.1016/j.neuroimage.2022.118994>.







- 314 [51] Engemann DA, Mellot A, Höchenberger R, Banville H, Sabbagh D,
315 Gemein L, et al. A reusable benchmark of brain-age prediction from
316 M/EEG resting-state signals. *NeuroImage* 2022;262:119521.
317 <https://doi.org/10.1016/j.neuroimage.2022.119521>.
- 318 [52] Giorgino T. Computing and Visualizing Dynamic Time Warping
319 Alignments in R: The dtw Package. *J Stat Softw* 2009;31:1–24.
320 <https://doi.org/10.18637/jss.v031.i07>.
- 321 [53] Sakoe H, Chiba S. Dynamic programming algorithm optimization for
322 spoken word recognition. *IEEE Trans Acoust Speech Signal Process*
323 1978;26:43–9. <https://doi.org/10.1109/TASSP.1978.1163055>.
- 324 [54] Knowland D, Lim BK. Circuit-based frameworks of depressive behaviors:
325 The role of reward circuitry and beyond. *Pharmacol Biochem Behav*
326 2018;174:42–52. <https://doi.org/10.1016/j.pbb.2017.12.010>.
- 327 [55] Kalin NH. The Critical Relationship Between Anxiety and Depression.
328 *Am J Psychiatry* 2020;177:365–7.
329 <https://doi.org/10.1176/appi.ajp.2020.20030305>.
- 330 [56] Sampogna G, Toni C, Catapano P, Rocca BD, Di Vincenzo M, Luciano
331 M, et al. New trends in personalized treatment of depression. *Curr Opin*
332 *Psychiatry* 2024;37:3. <https://doi.org/10.1097/YCO.0000000000000903>.
- 333 [57] Wei M, Qin J, Yan R, Li H, Yao Z, Lu Q. Identifying major depressive
334 disorder using Hurst exponent of resting-state brain networks.
335 *Psychiatry Res Neuroimaging* 2013;214:306–12.
336 <https://doi.org/10.1016/j.pscychresns.2013.09.008>.
- 337 [58] Liu Y, Postupna N, Falkenberg J, Anderson ME. High frequency deep
338 brain stimulation: What are the therapeutic mechanisms? *Neurosci*
339 *Biobehav Rev* 2008;32:343–51.
340 <https://doi.org/10.1016/j.neubiorev.2006.10.007>.
- 341 [59] Sani S, Busnello J, Kochanski R, Cohen Y, Gibbons RD. High-frequency
342 measurement of depressive severity in a patient treated for severe
343 treatment-resistant depression with deep-brain stimulation. *Transl*
344 *Psychiatry* 2017;7:e1207–e1207. <https://doi.org/10.1038/tp.2017.145>.
- 345 [60] McIntyre CC, Anderson RW. Deep brain stimulation mechanisms: the
346 control of network activity via neurochemistry modulation. *J Neurochem*
347 2016;139:338–45. <https://doi.org/10.1111/jnc.13649>.
- 348 [61] Iturrate I, Pereira M, Millán J del R. Closed-loop electrical
349 neurostimulation: Challenges and opportunities. *Curr Opin Biomed Eng*
350 2018;8:28–37. <https://doi.org/10.1016/j.cobme.2018.09.007>.
- 351















A**B****C**

A**B**

A**B****C**